The role of macrophages in allograft rejection

Transplantation

Volumn 80, Issue 12, 2005, Pages 1641-1647

  Wyburn, Kate R ^a   Jose, Matthew D ^b   Wu, Huiling ^a   Atkins, Robert C ^b   Chadban, Steven J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Allograft; Macrophage; Rejection

Indexed keywords

ALEMTUZUMAB; CYTOKINE RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN PRESENTATION; APOPTOSIS; CARDIAC GRAFT REJECTION; CELL FUNCTION; CELL PROLIFERATION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CYTOLOGY; EFFECTOR CELL; GRAFT REJECTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; KIDNEY GRAFT REJECTION; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TISSUE INJURY; TREATMENT OUTCOME;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY; MACROPHAGES;

EID: 30144445199     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000173903.26886.20     Document Type: Review

References (92)

1. BrentL, Brown J, Medawar PB. Skin transplantation immunity in relation to hypersensitivity. Lancet 1958; 2: 561.
2. van Furth R. Origin and turnover of monocytes and macrophages. Curr Top Pathol 1989; 79: 125.
3. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767.
4. Underhill DM, Bassetti M, Rudensky A, Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med 1999; 190: 1909.
5. Randolph GJ, GJ, Sanchez-Schmitz G, G, LiebmanRM, Schakel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002; 196: 517.
6. Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003; 171: 2262.
7. Delneste Y, Charbonnier P, Herbault N et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2003; 101: 143.
8. Hume DA, Ross IL, Himes SR, et al. The mononuclear phagocyte system revisited. J Leukoc Biol 2002; 72: 621.
9. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23.
10. Mackaness GB. The Immunological Basis of Acquired Cellular Resistance. J Exp Med 1964; 120: 105.
11. Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739.
12. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107.
13. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 7115.
14. Fernandez N, Renedo M, Garcia-Rodriguez C, Sanchez Crespo M. Activation of monocytic cells through Fc{gamma} receptors induces the expression of macrophage-inflammatory protein (MIP)-1{alpha}, MIP-1{beta}, and RANTES. J Immunol 2002; 169: 3321.
15. Tridandapani S, Siefker K, Teillaud J-L, et al. Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem 2002; 277: 5082.
16. Yada A, Ebihara S, Matsumura K, et al. Accelerated antigen presentation and elicitation of humoral response in vivo by Fc [gamma]RIIB-and Fc[gamma]RI/III-mediated immune complex uptake. Cell Immunol 2003; 225: 21.
17. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287.
18. Doyle AG, Herbein G, Montaner LJ et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol 1994; 24: 1441.
19. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol 2002; 168: 3697.
20. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002; 72: 101.
21. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890.
22. Barker RN, Erwig LP, Hill KS, et al. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin Exp Immunol 2002; 127: 220.
23. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301.
24. Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9: 4.
25. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50.
26. Christopher K, Mueller TF, Ma C, et al. Analysis of the innate and adaptive phases of allograft rejection by cluster analysis of transcriptional profiles. J Immunol 2002; 169: 522.
27. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 2002; 73: 853.
28. Chalasani G, Li Q, Konieczny BT et al. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004; 172: 7813.
29. Grau V, Herbst B, Steiniger B. Dynamics of monocytes/macrophages and T lymphocytes in acutely rejecting rat renal allografts. Cell Tissue Res 1998; 291: 117.
30. Paradis IL, Marrari M, Zeevi A, et al. HLA phenotype of lung lavage cells following heart-lung transplantation. J Heart Transplant 1985; 4: 422.
31. Penfield JG, Wang Y, Li S, et al. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney. Kidney Int 1999; 56: 1759.
32. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582.
33. Hancock WW, Thomson NM, Atkins RC. Composition of interstitial cellular infiltrate identified by monoclonal antibodies in renal biopsies of rejecting human renal allografts. Transplantation 1983; 35: 458.
34. Pilmore HL, Painter DM, Bishop GA, et al. Early up-regulation of macrophages and myofibroblasts: a new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 2658.
35. Croker BP, Clapp WL, Abu Shamat AR, et al. Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 1996; 57: S42.
36. Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997; 63: 414.
37. Pattison J, Nelson PJ, Huie P, et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994; 343: 209.
38. Grau V, Gemsa D, Steiniger B, Garn H. Chemokine expression during acute rejection of rat kidneys. Scand J Immunol 2000; 51: 435.
39. Lan HY, Yang N, Brown FG, et al. Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 1998; 66: 1465.
40. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171: 6929.
41. Jose MD, David JR, Atkins RC, Chadban SJ. Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection. Am J Transplant 2003; 3: 1099.
42. Demir Y, Chen Y, Metz C, et al. Cardiac allograft rejection in the absence of macrophage migration inhibitory factor. Transplantation 2003; 76: 244.
43. Grau V, Stehling O, Garn H, Steiniger B. Accumulating monocytes in the vasculature of rat renal allografts: phenotype, cytokine, inducible no synthase, and tissue factor mRNA expression. Transplantation 2001; 71: 37.
44. Scriba A, Grau V, Steiniger B. Phenotype of rat monocytes during acute kidney allograft rejection: increased expression of NKR-P1 and reduction of CD43. Scand J Immunol 1998; 47: 332.
45. Erwig LP, Rees AJ. Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Kidney Blood Press Res 1999; 22: 21.
46. Schenkel AR, Mamdouh Z, Chen X, et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143.
47. Kerr PG, Nikolic-Paterson DJ, Lan HY, et al. Deoxyspergualin suppresses local macrophage proliferation in rat renal allograft rejection. Transplantation 1994; 58: 596.
48. Le Meur Y, Jose MD, Mu W, et al. Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Transplantation 2002; 73: 1318.
49. Jose MD, Le Meur Y, Atkins RC, Chadban SJ. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant 2003; 3: 294.
50. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
51. Ozdemir BH, Demirhan B, Gungen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. Nephron 2002; 90: 442.
52. Karnovsky ML. Metchnikoff in Messina: a century of studies on phagocytosis. N Engl J Med 1981; 304: 1178.
53. Rabinovitch M. Professional and non-professional phagocytes: an introduction. Trends Cell Biol 1995; 5: 85.
54. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359.
55. Underhill DM, Bassetti M, Rudensky A, Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med 1999; 190: 1909.
56. Breloer M, More SH, Osterloh A, et al. Macrophages as main inducers of IFN-{gamma} in T cells following administration of human and mouse heat shock protein 60. Int Immunol 2002; 14: 1247.
57. Trieb K, Dirnhofer S, Krumbock N, et al. Heat shock protein expression in the transplanted human kidney. Transpl Int 2001; 14: 281.
58. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86.
59. Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281.
60. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.
61. Teppo AM, Honkanen E, Ahonen J, Gronhagen-Riska C. Does increased urinary interleukin-1 receptor antagonist/interleukin-1beta ratio indicate good prognosis in renal transplant recipients? Transplantation 1998; 66: 1009.
62. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1785.
63. Kutukculer N, Shenton BK, Clark K, et al. Renal allograft rejection: the temporal relationship and predictive value of plasma TNF (alpha and beta), IFN-gamma and soluble ICAM-1. Transpl Int 1995; 8: 45.
64. Abdallah AN, Billes MA, Attia Y, et al. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J 1997; 18: 1024.
65. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that a7nti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991; 51: 57.
66. Wyburn K, Wu H, Yin J, et al. Macrophage-derived interleukin-18 in experimental renal allograft rejection. Nephrol Dial Transplant 2005; 20: 699.
67. Halloran PF, Autenried P, Ramassar V, et al. Local T cell responses induce widespread MHC expression. Evidence that IFN-gamma induces its own expression in remote sites. J Immunol 1992; 148: 3837.
68. Diamond AS, Gill RG. An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts. J Immunol 2000; 165: 247.
69. Ring GH, Saleem S, Dai Z, et al. Interferon-gamma is necessary for initiating the acute rejection of major histocompatibility complex class II-disparate skin allografts. Transplantation 1999; 67: 1362.
70. Saleem S, Konieczny BT, Lowry RP, et al. Acute rejection of vascularized heart allografts in the absence of IFNgamma. Transplantation 1996; 62: 1908.
71. Halloran PF, Miller LW, Urmson J, et al. IFN-gamma alters the pathology of graft rejection: protection from early necrosis. J Immunol 2001; 166: 7072.
72. Ioannidis I, Hellinger A, Dehmlow C, et al. Evidence for increased nitric oxide production after liver transplantation in humans. Transplantation 1995; 59: 1293.
73. Worrall NK, Lazenby WD, Misko TP, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181: 63.
74. Holan V, Krulova M, Zajicova A, Pindjakova J. Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol 2002; 38: 989.
75. Roza AM, Cooper M, Pieper G, et al. NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation 2000; 69: 227.
76. Pearsall NN, Weiser RS. The macrophage in allograft immunity. I. Effects of silica as a specific macrophage toxin. J Reticuloendothel Soc 1968; 5: 107.
77. Unanue ER. Properties and some uses of anti-macrophage antibodies. Nature 1968; 218: 36.
78. Grone HJ, Weber C, Weber KS, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. Faseb J 1999; 13: 1371.
79. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35.
80. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199.
81. Jose MD, Ikezumi Y, van Rooijen N, et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76: 1015.
82. Yi S, Hawthorne WJ, Lehnert AM, et al. T cell-activated macrophages are capable of both recognition and rejection of pancreatic islet xenografts. J Immunol 2003; 170: 2750.
83. Tesch GH, Schwarting A, Kinoshita K, et al. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999; 103: 73.
84. Ikezumi Y, Hurst LA, Masaki T, et al. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003; 63: 83.
85. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.
86. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
87. Herrero-Fresneda I, Torras J, Cruzado JM, et al. Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127.
88. Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16: 137.
89. Shimizu A, Yamada K, Sachs DH, Colvin RB. Mechanisms of chronic renal allograft rejection. II. Progressive allograft glomerulopathy in miniature swine. Lab Invest 2002; 82: 673.
90. Azuma H, Nadeau KC, Ishibashi M, Tilney NL. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation 1995; 60: 1577.
91. Yang J, Reutzel-Selke A, Steier C, et al. Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft injury in a rat renal allograft model. J Am Soc Nephrol 2003; 14: 214.
92. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147.